"Liquidity is extending its gain to consumer oriented stocks and sectors, given positive development on upcoming monsoon. At the same time, dichotomy was seen in pharma, IT and high beta stocks due to headwinds on business outlook and NPA issues. This positive trend can continue in the near-term given strong domestic and FII inflows even though the valuation is high due to attractive outlook for earnings growth in the future," said Vinod Nair, Head of Research, Geojit Financial Services.
Healthcare stocks were the biggest drag on the index, after Sun Pharmaceutical Industries fell as much as 13.2% to a near four-year low after the company on Friday reported a 14% fall in March-quarter profit. The company said its US sales may fall this year on lower drug prices. The stock settled at Rs 500, down 12%.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)